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Abstract
Background: The efficient expansion in vitro of cytolytic CD8
+ T cells (CTLs) specific for autologous tumors is crucial both for
basic and translational aspects of tumor immunology. We investigated strategies to generate CTLs specific for autologous
Non-Small Cell Lung Carcinoma (NSCLC), the most frequent tumor in mankind, using circulating lymphocytes.
Principal Findings: Classic Mixed Lymphocyte Tumor Cultures with NSCLC cells consistently failed to induce tumor-specific
CTLs. Cross-presentation in vitro of irradiated NSCLC cells by autologous dendritic cells, by contrast, induced specific CTL
lines from which we obtained a high number of tumor-specific T cell clones (TCCs). The TCCs displayed a limited TCR
diversity, suggesting an origin from few tumor-specific T cell precursors, while their TCR molecular fingerprints were
detected in the patient’s tumor infiltrating lymphocytes, implying a role in the spontaneous anti-tumor response. Grafting
NSCLC-specific TCR into primary allogeneic T cells by lentiviral vectors expressing human V-mouse C chimeric TCRa/b chains
overcame the growth limits of these TCCs. The resulting, rapidly expanding CD4
+ and CD8
+ T cell lines stably expressed the
grafted chimeric TCR and specifically recognized the original NSCLC.
Conclusions: This study defines a strategy to efficiently induce and propagate in vitro T cells specific for NSCLC starting from
autologous peripheral blood lymphocytes.
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Introduction
The growth of transformed cells is controlled to some extent by
the immune system, a phenomenon termed tumor immunesur-
veillance (reviewed in [1]).
Compelling evidence for the involvement of CD8
+ cytotoxic T
lymphocytes (CTLs) in tumor immunosurveillance has emerged in
recent years with the cloning of genes encoding tumor associated
antigens (TAAs), and the subsequent molecular identification of
tumor-specific T cell epitopes [2,3,4]. The efficient induction in
vitro of CTLs specific for autologous tumors is critical for relevant
aspects of tumor immunology, including the generation of cellular
probes to exploit in the discovery of new TAAs or the expansion of
effector cells for adoptive immunotherapy approaches. Non-Small
Cell Lung Carcinoma (NSCLC) is the leading cause of cancer
death worldwide and responds poorly to current therapies
(reviewed in [5]). Systemic immunotherapy can be envisaged as
an attractive innovative therapeutic approach for this tumor.
However, the antigenic repertoire expressed by this tumor is still
poorly defined [6]. Devising an efficient strategy to induce and
expand in vitro T cells specific for the autologous tumor would be
critical to implement both antigen-discovery and active or
adoptive immunotherapy approaches in NSCLC.
The mixed lymphocytes tumor cultures (MLTC) have been
utilized as effective means to induce high numbers of T cells
specific for autologous melanoma [7,8,9,10,11,12]; however, their
application to other types of tumor has proved less favorable,
possibly owing to the reduced antigenicity and/or immunogenicity
of non-melanoma cancers. More recently, it became clear that a
major pathway for antigen presentation in vivo relies on the indirect
uptake of antigens, whether cell-associated or not, by Dendritic
Cells (DCs), the most powerful antigen presenting cells in the
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named ‘‘cross-presentation’’, can be successfully reproduced in vitro
owing to the possibility to grow DCs ex vivo, and works effi-
ciently with cell-associated, tumor-derived or viral antigens
[13,14,15,16,17].
T cell specificity is exclusively determined by the T cell
receptor (TCR), therefore the transfer into recipient polyclonal T
cells of TCR genes, isolated from a high affinity tumor-specific T
cell clone, generates T cell lines carrying the original clonotypic
tumor-specificity. TCR-grafted T cells have been demonstrated
to be functionally active both in vitro [18] and in vivo [19,20].
Recently, the first TCR gene therapy trial in patients with
melanoma demonstrated the clinical feasibility of the approach
[21]. Due to the competition for cell surface expression with the
endogenous molecules and the potential formation of mixed
TCRs, the expression level of the transduced TCR is frequently
reduced in comparison with the endogenous one, resulting in a
poor functional activity of engineered T cells [22]. Among the
strategies that have been implemented in order to maximize the
likelihood of the intramolecular pairing of grafted TCR a and
bchains in tranduced human T cells, a relatively straightforward
one utilizes chimeric human-mouse TCR a and bchains [23,24].
The chimeric TCRs consisting of a human variable and a mouse
constant region, in fact, disfavors the mispairing between the
transduced and the endogenous TCRchains, markedly increas-
ing the correct expression of the grafted TCR abheterodimers
[23].
In this study, we have systematically investigated strategies to
generate, propagate and expand CTLs specific for autologous
NSCLC from PBMCs, a convenient source of lymphocytes,
considering that it is not always possible to obtain tumor-
infiltrating lymphocytes (TILs) from patients. We demonstrate
that in vitro cross-presentation of NSCLC-derived tumor antigens
by autologous DCs is exceedingly more efficient than the classic
MLTC for the induction of tumor-specific CTLs. Furthermore, we
show that it is possible to overcome the poor in vitro growth and
expansion capacity of NSCLC-specific CTLs by grafting, via
lentivirus-mediated transduction, their human V-mouse C chi-
merc TCR a and b chain genes into primary allogeneic T cells.
This generates CD4
+ or CD8
+ T cell lines that stably express the
grafted TCR clonotype and can be easily expanded to substantial
numbers in vitro by standard culture conditions. Expression of the
chimeric TCR redirects recognition of the transduced allogeneic T
cells against the autologous NSCLC.
Results
MLTCs fail to induce NSCLC-specific CD8
+ T cells
To determine the best experimental approach to generate CD8
+
T cells specific for autologous NSCLC, a tumor cell line of the
large cell carcinoma subtype was established from the surgical
specimen of the CaPo13 NSCLC patient. CaPo13 cells expressed
HLA-B and C but not HLA-A isotypes, as detected by FACS
analysis (data not shown). To improve its immunogenicity, the cell
line was transduced with the costimulatory molecules CD80 (B7-
1), which was efficiently expressed on the cell membrane (data not
shown).
CaPo13-B7-1 cells were used to stimulate autologous PBMCs
according to established MLTC protocols. The frequency of CD8
+
T cells increased from the initial 16% (Figure 1A) up to 58% of the
cells in culture (Figure 1B) after one week of culture in the presence
of irradiated CaPo13-B7-1 cells, IL-2 and IL-7. The CD8
+ T cells
present in the culture were enriched by positive immunomagnetic
sorting, resulting in a population of 98% CD8
+ T cells (Figure 1C).
This polyclonal CD8
+ T cell line did not kill the autologous
CaPo13 tumor cell lines in a standard killing assay (Figure 1E). A
weekly restimulation regimen with irradiated CaPo13-B7-1 cells
and cytokines did not expand T cells able to kill the autologous
tumor cells. Instead, three or four rounds of restimulation lead to a
progressive replacement of the CD8
+ T cells with CD4
+CD8
+ DP
ones (Figure 1D), endowed with antigen non-specific killing
activity (data not shown). This result was consistently obtained
in two subsequent MLTC attempts.
After cloning the CD8
+ T cells at the time of CD8-
immunomagnetic enrichment, we could identify only one T cell
clone (TCC), out of 500 tested, which specifically recognized
autologous NSCLC cells. TCC 22N expressed CD8 (Figure 1F)
and produced IFNc following the specific recognition of CaPo13
cells in a MHC class I restricted manner (Figure 1G–H).
An independent set of MLTCs performed with a NSCLC cell
line established from the tumor of a different patient resulted in the
induction of a tumor non-specific DP T cell population, expanded
from the patient’s PBMCs (data not shown).
Collectively, this set of data suggested that the MLTC approach
is unsuitable to efficiently induce CTLs specific for the autologous
tumor from PBMCs in the NSCLC setting.
Efficient induction of NSCLC-specific CD8
+ T cells by
DC-mediated cross-presentation of autologous irradiated
tumor cells
We next evaluated the capacity of inducing anti-tumor CTLs in
vitro by cross-presentation of irradiated CaPo13 cells using
autologous DCs and purified autologous T cells. After two rounds
of weekly restimulations, the culture contained 70% of CD8
+ T
cells (data not shown) that displayed a specific and vigorous killing
against the autologous tumor cell lines (Figure 2A).
The high frequency of tumor-specific CD8
+ T cells contained in
the cell line was confirmed by the rapid screening of the TCCs
obtained by limiting dilution: 52 out of 184 tested clones produced
IFNcin response to autologous CaPo13 and not to K562 cells
(Figure 2B and data not shown). TCCs specific for CaPo13 cells
expressed the CD8 coreceptor (Figure 3A) and recognized the
autologous lung cancer cell line in a HLA class I restricted
manner, but not antigen-unrelated target cells, including the
autologous Capo13 LCL line and the allogeneic, HLA-unrelated
melanoma cell line LB-40 (Figure 3B and 3C).
Together, these data suggested that DC cross-presentation of
tumor-derived antigens to autologous T cells in vitro is an efficient
strategy to induce and expand tumor-specific CD8
+ T cells also in
the NSCLC setting.
Limited TCR clonal heterogeneity of the T cell clones
specific for the autologous CaPo13 NSCLC
To investigate the clonal composition of the NSCLC-specific T
cell response induced in vitro by DC-mediated cross-presentation of
tumor-associated antigens, the TCRVb and Va repertoire of 10
selected CaPo13-specific TCCs was investigated by RT-PCR
using a panel of oligonucleotide primers specific for 29 Va and 24
Vb families respectively. These clones were selected for exhibiting
a consistently greater response to CaPo13 cells. The analysis
showed the presence of sister clones, sharing identical TCRs
(Table 1) as confirmed by sequencing analysis. Globally, we
identified four different TCR clonotypes expressed by the
CaPo13-specific CD8
+ T cell clones induced by DC cross-
presentation plus one T cell clonotype induced by MLTC,
suggesting the expansion in vitro of a limited number of T cell
precursors specific for the autologous NSCLC.
Lung Cancer-Specific T Cells
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isolated in vitro are detected in TILs
To determine whether the NSCLC-specific CD8
+ T cell clones
isolated in vitro might have played any role in the spontaneous anti-
tumor response in vivo, we investigated whether the molecular
fingerprints of the NSCLC-specific TCR clonotypes identified in
this study were present at the tumor site. Mononuclear cells
infiltrating the CaPo13 tumor specimen were thawed and part of
them immediately processed for RNA extraction (primary TILs),
while a part was expanded in vitro by culturing for 10 days in the
presence of IL-2 (20 IU/ml) and either irradiated CaPo13 cells or
anti-CD3 mAb. The TCR Va and Vb chains of three out of five
TCR clonotypes analyzed were detected in TILs (TCC 22N, TCC
CL3, TCC CL54). The molecular fingerprints of TCC3 (Figure 4)
and TCC1 (not shown) could not be detected in any experimental
condition. TCC CL3 TCR fingerprint was undetectable in the
TIL sample expanded by anti-CD3 mAb stimulation, as compared
to the sample obtained ex vivo or expanded in vitro by CaPo13 cells.
This suggested that TCC CL3 could be outcompeted in vitro by the
growth of other TCCs present in TILs that responded better to the
polyclonal stimulus. Indirectly, this result also confirmed that TCC
CL3 was specific for the autologous tumor cells. The presence of
three out of five clonotypes among TILs was confirmed by
heteroduplex analysis (data not shown).
Altogether, these findings suggested that the NSCLC-specific
CD8
+ TCCs isolated in vitro participated in the immune
surveillance of the autologous tumor in vivo.
Propagation and expansion of CaPo13-specific TCC CL3
TCR clonoype by TCR transfer into primary allogeneic T
cells
To overcome the technical hurdle represented by the poor
expansion of these TCCs in vitro by standard culture conditions,
we sought to transfer the CaPo13-specific TCR clonotypes into
fast growing primary allogeneic T cells. We generated chimeric
TCR molecule containing the human V region linked to the
murine C region, with the threefold purpose to: i enhance the
correct TCR a/b pairing of the exogenous chains; ii disfavoring
mis-pairing with the endogenous TCR a and b chains; and iii
improve the assembly with the human CD3 complex [23,25].
Moreover, the presence of the mouse Cb region expressed by the
chimeric TCR would also permit its specific detection in human
T cells, thanks to a mAb specific for the mouse TCR Cb.A sa
proof of concept, we sought to transfer the TCR expressed by
TCC CL3 because it expressed the Va 12 and Vb 13.1 gene
segments that are recognized by specific mAbs, facilitating their
tracking upon transduction into allogeneic T cells. Futhermore,
the molecular fingerprint of this TCR was detected in the TILs
of CaPo13 patient. The chimeric TCR a and b chain of TCC
CL3 were cloned as a single transcriptional cassette under the
control of a common SFFV (spleen focus forming virus)
promoter into the pHRSIN-Bx-IRES-Em lentiviral vector. As
shown in Figure 5A, 72 hours after transduction (day +5), 38%
of policlonally activated T cells co-expressed the transduced
TCR Va12/Vb13.1. This frequency was markedly increased in
comparison to that of the same TCR V regions pairing in non-
transduced T cells (0,7%, data not shown), indicating that the
bicistronic lentiviral vector efficiently transferred the chimeric
TCR ˜ ab into PBMCs. The frequency of cells expressing the
transduced chimeric TCR CL3, however, decreased markedly
already by day 12 after transduction (Figure 5B) and reached
background levels (i.e. untransduced T cells) by day 15. Cell
sorting for the expression of the TCR CL3-transduced T cells
followed by a polyclonal stimulation with anti-CD3 mAb,
allogeneic irradiated PBMC and hrIL-2 did not rescue the
surface detection of the chimeric TCR (data not shown).
However, two to three weekly antigen-specific restimulations of
the TCR CL3-transduced T cells with irradiated CaPo13 cells,
coupled with a round of cell sorting of T cells expressing the
transduced chimeric TCR Va12/Vb13.1, resulted in a popula-
tion of T lymphocytes that displayed a nearly homogenous
expression of the transduced TCR over time (Figure 5C). Once
established by this protocol, the TCR CL3-transduced T cell
lines could be maintained and expanded by polyclonal




+ T cell stably transduced with a
NSCLC-specific chimeric TCR recognize CaPo13 tumor
cells
We next sorted for CD4 and CD8 expression the T cells
homogenously and stably expressing the transduced TCR CL3
and tested them for the recognition of CaPo13 cells. As shown in
Figure 5 E–F, both CD4
+ and CD8
+ TCR CL3 transduced T cells
(CL3 TCR
+CD4
+ and CL3 TCR
+CD8
+) produced IFNc in a
HLA class I-restricted manner upon recognition of CaPo13 cells.
Production of IFNc upon recognition of CaPo13 cells by both the
original TCC CL3 and the CL3 TCR
+CD8
+ T cells occurred also
in the presence of anti-CD8 blocking mAb (figure 5 F–G). This
demonstrated the coreceptor independence of CL3 TCR and it
was consistent with the recognition of CaPo13 cells also by the
CL3 TCR
+CD4
+ transduced T cells. Although CL3 TCR
+CD4
+
cells efficiently produced IFNcin response to an Ag-specific
stimulation, they produced negligible quantities of IL-2 (mean
6.5 pg/ml; unstimulated control T cells ,1 pg/ml), suggesting
that these cells exhibited essentially an effector-memory phenotype
owing to the recurrent stimulations in vitro in the presence of IL-2.
A different stimulation protocol in vitro, based on the use of IL-7
amd IL-15 in lieu of IL-2, plus anti-CD28 costimulation, might be
required in order to expand TCR-tranduced T cells endowed with
IL-2 production [26].
The sensitivity of transduced CD4
+ and CD8
+ T cell lines for
the specific target were directly compared by co-culturing them
with CaPo13 cells diluted at different percentages into irrelevant
COS7 cells. CL3TCR
+CD4
+ cells displayed an 8 times higher
Ag-specific responsiveness than the CL3 TCR
+CD8
+ ones and
were still able to produce IFNcwhen CaPo13 cells were diluted
1:500 (Figure 6A). This could be explained by the greater
intrinsic capacity of the CD4
+ subset to produce IFNc upon
activation, as suggested by the different response of the two
Figure 1. MLTCs fail to induce NSCLC-specific T cells. PBMCs from CaPo13 patients were cultured in vitro with irradiated autologous NSCLC
cells engineered with CD80/B7-1. T cell line phenotype A) at the time of induction and B) after one week of MLTC; C) CD8
+ enrichment by
immunomagnetic sorting; D) induction of DP cells after the fourth restimulation; E) citotoxicity test performed on the specific targets CaPo136 B7.1
and on the NK target K562; F) CD8 expression by the single NSCLC-specific TCC 22N obtained by cloning the T cell line depicted in C; G) IFNc
production by TCC 22N after co-culture with the specific target CaPo13 cells, the NK cell K562 target, the autologous CapoLCL cell line, the unrelated
melanoma cell line LB-40; H) TCC 22N recognition of CaPo136 the indicated HLA-blocking mAbs. Panels A–F show one representative experiment of
three independent MLCTs performed. Panels G–H show one representative experiment of two performed.
doi:10.1371/journal.pone.0012014.g001
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(Figure 6B). However, only CL3 TCR
+CD8
+ cells displayed
tumor-specific citolytic potential, as suggested by the up-
regulated CD107a upon co-culture with CaPo13 cells in these
cells and not in the CL3TCR
+CD4
+ ones (Figure 6C and data
not shown). CL3 TCR
+CD8
+ cells killed in a MHC class I-
restricted manner CaPo 13 cells also in classic 4 h
51Cr-release
assays (Figure 6D), confirming that the CL3 TCR transfer
endowed these allogeneic T cells with actual NSCLC-specific
killer effector functions.
Discussion
In this study we explored ways of generating CTLs directed
against NSCLC from autologous PBMCs. We showed that
conventional MLTCs, in which PBMCs are co-cultured with an
autologous NSCLC cell line, was inefficient in inducing tumor-
specific T cells. Moreover, MLTCs resulted in the induction of T
cell lines displaying CD4
+CD8
+ DP phenotypes and non-specific
killing activity. It is unclear why direct presentation of tumor-
antigens to autologous T cells by NSCLC cells should result in the
Figure 2. CD8
+ T cell lines induced in vitro by DC-mediated cross-presentation specifically kill autologous CaPo13 cells.
Immunomagnetically purified CD8
+T cells were cultured with autologous DCs, both irradiated CaPo13 lung cancer cells and CD4
+ T cells, hrIL-7 and
hrIL-12. A) Citotoxicity assay performed after two rounds of stimulation on the specific target CaPo13 cells CaPo136 B7.1 and on the NK cell target
K562; B) TCCs obtained by limiting dilution were co-cultured overnight with the specific target CaPo13 (black bars) or the NK cell target K562 (grey
bar). IFNc secretion was determined by ELISA. Clones were considered specific for the autologous NSCLC cells CaPo13 if their IFNc production was at
least three times higher than the one induced upon recognition of the NK target. The graph shows the results of the rapid screening with the first 42
TCCs obtained.
doi:10.1371/journal.pone.0012014.g002
Lung Cancer-Specific T Cells
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derive from purified CD8
+ T lymphocytes (homogenously
negative for CD4 expression) stimulated three-four times in
MLTCs with the autologous tumor cells. It is possible that these
cells derive from CD8
+ T cells that have upregulated the CD4
coreceptor generating DP T cells endowed with antigen non-
Figure 3. Characterization of the NSCLC-specific CD8
+ TCC obtained by in vitro cross-presentation. TCCs responding to CaPo13 and not
to K562 cells upon rapid screening were retested against a variety of targets to confirm their specificity. A) CD8 coreceptor expression of
representative TCCs; B) TCCs recognition of CaPo13 cells in the presence or not of antibodies blocking HLA molecules; C) IFNc production by selected
TCCs after overnight co-culture with the specific target CaPo13, the NK specific target K562, the autologous cell line CapoLCL and the unrelated
melanoma cell line LB-40. Representative clones are shown. Panel B-C show one representative experiment of two performed.
doi:10.1371/journal.pone.0012014.g003
Lung Cancer-Specific T Cells
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12014specific effector functions. CD8
+ T cells were indeed shown to
upregulate CD4 after activation [27]. Alternatively, the antigen
non-specific DP T lymphocytes cells could represent a pre-formed
population, which is present at very low frequency at the
beginning of the culture and progressively expanded upon
interaction with autologous lung cancer cells. DP T cells endowed
with non-specific killing activity were obtained by MLTC with
renal cancer cells [28], suggesting that MLTC with tumor cells
other then melanoma might often result in the induction of this
kind of T cells.
By the combined use in vitro of DCs, irradiated CD4
+ T helper
cells, IL-12 and IL-7, we have demonstrated that cross-
presentation of dying tumor cells resulted in the generation of a
higher number of tumor specific TCCs, compared to any other
published attempt to induce NSCLC specific CTL clones by
MLTCs. We have elaborated this in vitro culture system from the
notion that optimal induction of CD8
+ T cells specific for
exogenous antigens in vivo requires the combination of DC
dependent cross presentation, help by CD4
+ T cells and the
addition of IL-12 and IL-7, whose presence was shown to be
critical for the efficient induction of anti-tumor effector T cells by
Montagna et al [15]. IL-12 and IL-7 were utilized in the induction
phase of the tumor-specific T cell response in vitro, because of the
known function of IL-12 in directing the acquisition of strongly
anti-tumor Th1/Tc1 effector functions, and of IL-7 in supporting
the growth of human CD8
+ T cells [29,30,31].
Despite the large number of TCCs obtained by DC-mediated in
vitro cross-presentation, the diversity of the TCR repertoire
displayed by these cells clones was restricted to four different
TCR clonotypes. This does not seem to be an anomaly in the
CD8
+ T cell response. In general, the clonal heterogeneity of
CD8
+ T cell response specific for exogenous (microbial or viral)
antigens is quite limited, yet it is sufficient to control infections
[32,33]. Furthermore, in melanoma patients, the CD8
+ T cell
responses specific for immunodominant epitopes derived from the
self shared tumor antigens MelanA/Mrt1 or NY-ESO1 display
also a limited clonal heterogeneity. Therefore, the little clonal
Table 1. The TCR repertoire of anti-CaPo13 T cell clones
displays a limited diversity.
TCC TCR Va Ja Vb Jb Cb Clonotype
22N 13.1 27 3 1.1 1 I
CL3 12 40 13.1 2.1 2 II
CL8 12 40 13.1 2.1 2 II
CL38 12 40 13.1 2.1 2 II
CL54 20 15 5.2 1.6 1 III
CL10 20 15 5.2 1.6 1 III
CL85 20 15 5.2 1.6 1 III
CL77 73 7 72 . 7 2 I V
TCC1 73 7 72 . 7 2 I V
TCC3 13 1 62 . 7 2 V
T cell clones with the same TCR a and b chains are grouped in the same
clonotype. The first TCR clonotype listed, CL22N, represents the only tumor-
specific TCC obtained by MLTC.
doi:10.1371/journal.pone.0012014.t001
Figure 4. TCR molecular fingerprints of the selected NSCLC-specific TCCs in TILs. The presence of the NSCLC-specific TCR clonotypes
isolated in vitro was determined by PCR-oligotyping in TILs of the CaPo13 patient. PCR oligotyping was performed for both TCR a and b chains. A
probe specific for the constant region (C), which therefore hybridizes with any PCR product, is used as control. The agarose gel was blotted onto
nylon filters, and hybridized sequentially with a probe specific for the TCR a and b N-regions and for the TCR C a and b regions. Four TCC clones are
shown.
doi:10.1371/journal.pone.0012014.g004
Lung Cancer-Specific T Cells
PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12014Lung Cancer-Specific T Cells
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12014diversity exhibited by the NSCLC-specific CD8
+ T cell clones that
we have isolated might reflect the intrinsic physiological property
of the CTL response, and this TCR clonality could be large
enough to support the potential recognition of different antigenic
epitopes expressed by NSCLC cells.
The NSCLC-specific T cell clonotypes that we have isolated in
vitro may be representative of the spontaneous anti-tumor response
elicited in vivo by the presentation of TAA to the patient’s T
lymphocytes. In support of this, we have detected the TCR
fingerprints of three out of five of these clonotypes in the TILs
isolated from the autologous tumor, suggesting that these three
TCR clonotypes may be involved in the spontaneous anti-tumor
response. The two clonotypes that were not found could either not
be present or present below the detection limits of the PCR-
oligotyping in the tumor site at the time of surgery. Alternatively, it
is possible that these two TCR clonotypes were primed in vitro
against the autologous lung cancer by DCs.
We showed that it is possible to overcome the difficulties to
maintain in culture CTLs specific for self-antigens by transferring
their TCR into allogeneic polyclonal T cells, which could be easily
expanded in culture. Tracking the expression of the transferred
TCR is a critical issue to determine the frequency of transduced T
cells and the degree of mispairing between the transferred and the
endogenous TCR a and b chains. This can be done by using
mAbs specific for the Va and Vb regions of the transduced TCRs
or by the use of multimers of the cognate MHC-peptide complex
recognized by the transduced TCR. However, TCR V region-
specific or MHC-peptide tetramers are not always available. The
use of chimeric TCR a and b chains with human V and mouse C
domains might, at least in part, overcome these problems not only
by increasing the amount of exogenous homologous TCRab
pairing [23,24], but also by enabling the tracking of the grafted
TCR molecules in transduced human T cells by using mAbs
specific for the mouse Cb region, regardless the availability of
TCR Va and/or Vb specific mAbs.
We successfully transduced the CL3 TCR chimeric a and b
chains in around 20–40% of peripheral blood derived human T
cells in all performed infections (data not shown), as detected three
days after infection. We constantly observed a decrease in the
frequency of T cells expressing the transduced TCR already by
day +5 post-infection. Furthermore we observed the same decrease
after polyclonal restimulation of the transduced CL3 TCR
+ T cells
enriched by FACS sorting. We do not have at present a ready
explanation for the rapid loss of the grafted TCR surface
expression in transduced primary human T lymphocytes. A
simple explanation could be the lack of transgene integration in
the majority of transduced T cells. Infecting primary T cells at the
same MOI with the control vector carrying the GFP as transgene,
however, resulted in a stable percentage of GFP expressing T cells
over time (data not shown). On the other hand, the transduction of
the lentiviral vector carrying the CL3 TCRa and b chain into
human primary T cells did not result in a proliferative
disadvantage or increased cell death compared to the untrans-
duced T cells (G. Canderan, data not shown).
However, consistent with published data [34], cyclic antigen-
specific stimulations successfully stabilized the expression of the
transferred CL3 TCR in the transduced T cells. It is possible that
the progressive stabilization of the transferred CL3 TCR
expression on the membrane of the transduced T cells might be
due to a selection in culture of a limited set of T cell clones whose
endogenous TCR is permissive for the expression of the exogenous
one. Future analysis of the clonal composition of long-lasting T cell
lines expressing the transduced CL 3 TCR will contribute to
address this issue.
We showed that, in addition to CD8
+, also CD4
+ T cells
expressing the transduced TCR CL3 efficiently recognized
CaPo13 cells. This is consistent with the CD8-independence of
the original TCC CL3 clone. Actually, the CL3 TCR
+CD4
+ T
cells display a somewhat higher responsiveness against CaPo13
target cells than the CL3 TCR
+CD8
+, based on their IFNc
production, reflecting their higher intrinsic efficacy as inflamma-
tory cells. This aspect may be interesting in the perspective of a
clinical application of TCR transfer in selected CD4
+ or CD8
+ T
cells for adoptive immunotherapy of cancer. The use of CD8 co-
receptor independent tumor-specific TCRs would permit to
exploit both CD4
+ and CD8
+ T-specific effector functions.
In conclusion, this study defines a strategy to efficiently induce
and propagate in vitro high numbers of T cells carrying a TCR
specific for autologous NSCLC. This strategy may be easily
adapted to all form of human malignancies. Furthermore, given
that the T cell clones isolated are representative of an anti-tumor
response spontaneously aroused in the CaPo13 patient, the
identification of the antigens recognized by them might give
interesting clues on the NSCLC/host immune system interactions.
Materials and Methods
Ethics Statement
The publication of the data obtained in this study with the lung
cancer cell line CaPo13 has been authorized by the Institutional
Ethical Committee of San Raffaele Scientific Institute (#08-04-
2010) in the light of the consideration that this cell line was
established from the surgical specimen of a patient before 2002,
when the approval of the Institutional Ethical Committee for such
procedures for research purposes became formally required by
national law.
Cell cultures
CaPo13 and MR232 NSCLC cell lines, LB-40 melanoma cell
line (kindly obtained from Ludwig Institute of Cancer research,
Bruxelles), K562 cell line (ATCC CCL 243), transduced T cell
lines and LCL cell lines were kept in complete RPMI 1640
medium containing 10 U/ml penicillin and streptomycin, 2 mM
L-glutamine, 1 mM sodium pyruvate, 1% non-essential amino
acids (Gibco) supplemented with 10% heat-inactivated FCS
(Euroclone) (RPMI-FCS). T cell clones (TCCs) were grown in
complete RPMI medium supplemented with 5% human serum
(RPMI-HS) and cytokines as indicated in text. 293T cells were
Figure 5. Selection of TCC CL3 TCR transduced allogeneic T cells specific for CaPo13 cells. Allogeneic T cells were transduced two days
after activation with a lentiviral vector encoding the chimeric TCC CL3 Va12-Ja40-mouse Ca and Vb13.1-Jb2.1-mouse Cb TCR chains. Expression of
the transferred TCR was detected on transduced T cells: A) at day 5 from activation; B) at day 12 from activation; C) after one cell sorting with anti-
mouse TCRb mAb and two rounds of stimulation with irradiated CaPo13 cells; D) after two rounds of polyclonal stimulation following the last
stimulation with irradiated CaPo13 cells. Ag-specific response and TCR expression of E) cell sorted CL3 TCR
+ CD4
+ cell line; F) cell sorted CL3 TCR
+
CD8
+ cell line and G) the original TCC CL3 cultured with the autologous NSCLC CaPo13 cells 6 anti-HLA-I, anti-HLA-DR or anti-CD8 blocking mAbs.
IFNc production was determined by standard ELISA. Cells were stained with anti-CD3, anti-Va12, anti-Vb13.1, anti-CD8 or anti-CD4 mAbs. One
representative experiment of three performed is shown.
doi:10.1371/journal.pone.0012014.g005
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streptomycin, 2 mM L-glutamine and 10% heat-inactivated FCS.
Establishment of CaPo13 NSCLC cell lines
Single cell suspension was prepared by digesting finely chopped
tumor sample with 1 mg/ml collagenase, 0,1 mg/ml hyaluroni-
dase and 0,02 mg/ml DNAse (Sigma) at 37Cu for 4 h. Tumor
samples were obtained from the routine pathological analysis of
the surgical specimens. Tumor cells were separated from
infiltrating lymphocytes on a 1.077-1.055 discontinuous Ficoll
gradient and plated in flasks in complete RPMI-1640 medium and
D-Valine to inhibit fibroblasts outgrowth [35]. Tumor-infiltrating
lymphocytes (TILs) were collected and frozen. Early-passage
tumor cell lines were used to minimize possible modifications of
primary characteristics as a consequence of extensive in vitro
culturing. B-lymphoblastoid cell lines (Capo-LCL) were estab-
lished from the patient cryopreserved PBMCs by the incubation
with EBV-containing supernatant from the B95.8 cell line
(ATCC). CaPo13 were transduced with the retroviral vector
LXSDN [36] carrying the reporter gene NGFR and the CD80
cDNA. Cells expressing NGFR were isolated by immunomagnetic
sorting (Dynabeads).
Induction of anti-CaPo13 T cell lines by autologous
MLTCs
CD80-tranduced CaPo13 cells (CaPo13-B7-1) were irradiated
at 100 Gy and plated with autologous PBMCs at the ratio of
3610
4 NSCLC cells for 1,5610
6 PBMCs in complete RPMI-HS
medium. After 48 h 10 IU/ml hrIL-2 (Roche) and 5 ng/ml hrIL-7
(R&D Systems) were added.
Cross-priming of tumor-specific T cells in vitro
CaPo13-specific CTL-lines were generated by a modification of
a published protocol [15]. Autologous dendritic cells were
obtained from PBMC according to published protocols [15].
CD8
+ T cells were isolated from PBMCs by positive immuno-
magnetic sorting (Miltenyi Biotec). Complete RPMI-HS medium
was further supplemented with 10 ng/ml IL-7 (R&D Systems) and
10 pg/ml IL-12 (R&D Systems). For induction of anti-tumor CTL-
lines, patient’s CD8-enriched PBMCs (0.5 to 1610
6 cells/ml)
were added to 48-well plates and co-cultured with irradiated
(100 Gy) autologous CaPo13 cells (5610
5 cells/ml), irradiated
(60 Gy) autologous CD8-deprived PBMCs (3 to 5610
5 cells/ml)
and autologous DCs (2610
5 cells/ml) in a final volume of 1 ml.
After 7 to 10 days, cultures were restimulated with irradiated
(100 Gy) CaPo13 (5610
5 cells/ml) and irradiated (60 Gy)
autologous PBMCs. Two days later, 25 IU/ml of hrIL-2 were
added to the cultures. The same protocol was used for each
successive round of stimulation.
51Cr-release assay
Cytotoxic activity of CTL-lines was tested in an 4 hr
51CR-
release assay as described [37], using an effector/target (E/T) ratio
that ranged between 30:1 and 5:1. Results are expressed in lysis
percentage for each E/T ratio using the sequent formula Lysis %
= (CPM-CPM spontaneous release)/(CPM total release-CPM
spontaneous release) 6100.
Isolation and expansion of T-cell clones specific for the
autologous CaPo13 NSCLC cells
Polyclonal CTL lines recovered after two rounds of CaPo13-
specific stimulation were cloned as described [38]. After 12 to 14
days of culture, all growing wells were harvested and expanded in
the presence of 100 IU/ml IL-2, phytohemagglutinin (PHA,
1 mg/mL), and allogeneic irradiated feeder cells (2610
6 cells/ml).
The TCCs obtained were screened for IFNc secretion in response
to CaPo 13 cell stimulation by standard ELISA (Pierce Endogen).
TCCs that reacted positively to CaPo13 were re-tested for their
ability to recognize the specific target cell line CaPo13 and not the
non-specific melanoma cell line LB-40 or the NK specific cell line
K562. CTL clones (8610
3) were added to target cells (2610
4)i n
96-well plates in complete RPMI-HS medium. Cell cultures were
performed in the presence or absence of CaPo13 and different
concentration of anti-HLA class I (W6/32) or anti-HLA-B-C (4E)
mAbs. Supernatants were collected 48 hours later and the IFNc
concentration determined by standard ELISA.
TCR repertoire analysis
Total RNA from CTLs, isolated with TRIZOL (Invitrogen), was
converted into cDNA and PCR amplified using a panel of 29
forward TCR Va specific and 24 Vb specific oligonucleotide
primers with reverse oligonucleotide primers complementary to
the TCR C a or b region as described [39,40].
Oligotyping analysis on TILs
Frozen TILs were thawed and either immediately lysed for
RNA extraction or expanded in vitro by CaPo13-specific
stimulation (100 Gy irradiated CaPo13 cells) or by polyclonal
stimulation (30 ng/mL OKT3 and 2610
6/ml 60 Gy irradiated
feeders) in the presence of 100 IU/mL hrIL-2. Total RNA from
the anti-CaPo13 TCCs and from the stimulated or unstimulated
TILs was converted into cDNA and PCR amplified with
oligonucleotide primers specific for the TCR V a and b segments
expressed by each TCC and for TCR Ca and b regions (listed in
[39,40]). The PCR profile was: 10 min at 94uC followed by 30 s at
94uC, 30 s at 61uC and 30 s at 72uC for 35 cycles, and final
10 min at 72uC. The PCR products were run on a 1.5% agarose
gel and blotted onto nylon membranes (Hybond, Amersham).
Oligonucleotide probes specific for the TCR a and b chain N–
regions (Table S1) of the 5 anti-CaPo13 TCCs were labelled and
hybridized as described [40].
Generation of lentiviral vector carrying the CL3 TCR a/b
chimeric chains
The V-J TCRa and TCRb gene segments of TCC CL3 TCR
were amplified by PCR and cloned in frame with mTCR Ca and
Cb. The chimeric human Vb13.1-mouse Cb and human Va12-
mouse Ca were subcloned into the pIRES vector (Clontech). The
Figure 6. TCR-transduced CD4
+ and CD8
+ T cells have different Ag responsiveness. The tumor-specificity, responsiveness and cytolytic
potential of the CL3 TCR
+ CD4
+ and CL3 TCR
+ CD8
+ T cell lines were investigated. A) CL3 TCR CD4
+ and CD8
+ T cells were cultured with CaPo 13 cells
diluted into COS7 cells at different percentages; B) CL3 TCR CD4
+ and CD8
+ T cells were activated or not with PMA and Ionomycin. After 48 h, IFNc
production was determined by standard ELISA. C) CL3 TCR CD8
+ cells were cultured with the specific target CaPo13, the unrelated NSCLC cell line
MR232 and the autologous cell line CapoLCL for 5 hours and then analysed for CD107a expression. One representative experiment of two performed
is shown. D) CL3 TCR CD8
+ cells were cultured with
51Cr-labelled CaPo13 for 4 h with or without the addition of mAbs specific for either MHC class I
(HLA-A, B, C) or MHC class II (HLA-DR), and killing was determined as described [15]. One representative experiment of two performed is shown.
doi:10.1371/journal.pone.0012014.g006
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primer containing a Bcl2 restriction site (pIRES for 59 AGTCT-
GATCACGACTCACTATAGGCTAGCCTCG; pIRESrev 59
CCTCA CTAAAGGGAAGCGGC). The amplicon was digested
with Bcl2 and NotI and cloned into the lentiviral vector pHRSIN-
Bx-IRES-Em (kindly provided by Dr V. Cerundolo, Univ. of
Oxford).
Production of lentiviral vectors carrying the chimeric TCC
CL3 TCR
Vector stocks were produced by Ca2PO4 transient transfection
of 293T cells using a second-generation lentiviral vector system
following published protocols. Breefly, subconfluent 293T cells in
15 cm dish were transfected with 12 mg, 16,25 mg and 6,25 mgo f
the pMD2.VSV-G, pCMVdR8.74 and pRSV-Rev packaging
plasmid [41,42] respectively (kindly provided by Dr Luigi Naldini,
San Raffaele Scientific Institute), mixed with 32 mg transfer vector
plasmid pHRSIN-CL3TCRab. Sixteen hours after transfection
medium was replaced and virus was collected 30 hours after
transfection. After filtering through a 0,22 mM filter (Millipore), the
vector was purified and concentrated by ultracentrifugation at
20000 g. The average titer was evaluated on TCR deficient Jurkat
76 cells [24] by adding serial dilutions of concentrated vector to
2.5610
5 cells in a 48-well plate (Nunc). Cells were analyzed
96 hours after transduction for CL3 TCR expression by flow
citometry. Transducing units were calculated using the sequent
formula (number of cells in the well at the time of transduction) 6
(frequency of TCR positive cells) 6 (dilution factor)/volume of
inoculum in mL = TU/mL.
Transduction of allogeneic PBMCs by lentiviral vector
carrying the chimeric TCC CL3 TCR
PBMCs were isolated from buffy coats by Ficoll-Hypaque
gradient separation (Pharmacia). T cells were activated with anti-
CD3/CD28 immunomagnetic beads (Dynabeads) according to
manufacturer’s instructions and kept in RPMI-FCS complete
medium supplemented with 5 ng/ml IL-15 and IL-7 (R&D
systems). Two days after activation, 4610
5 T cells were infected in
500 ml complete medium at a multiplicity of infection (MOI) of 5
in a 48-well plate. Cells were infected overnight and then washed
from the virus. After 72 h from infection, cells were stained with
Va12-FITC (Pierce Endogen) and Vb13.1-PE (Beckman coulter)
mAbs, fixed by paraformaldehyde (1%) and then analyzed by
flowcytometry.
Expansion and selection of TCC CL3 TCR transduced
allogeneic T cells
Transduced allogeneic T cells (1610
6) were stimulated weekly
with irradiated (100 Gy) CaPo13 (2610
5) and irradiated (100 Gy)
RosiEBV LCL cells (2610
4) in 1 ml complete RPMI FCS medium
supplemented with 100 IU/mL IL-2. Transduced cells underwent
one or more cycles of cell sorting to enrich for TCC CL3 TCR
expression by staining with mAb specific for mouse TCRb (BD
biosciences). Transduced T cells expressing either CD4 or CD8
coreceptor were obtained by cell sorting using co-receptor specific
mAbs. Transduced T cells homogenously positive for TCC CL3
TCR surface expression (1610
6) were expanded by polyclonal
stimulation (30 ng/mL OKT3, 25610
6 cells irradiated feeders
(60 Gy), 5610
6 cells irradiated RosiEBV (100 Gy), 600 IU/mL
rhIL-2) in 25 ml complete RPMI FCS medium.
Activation in vitro of CD4
+ and CD8
+ T cells transduced
with the chimeric TCC CL3 TCR
Specific T cell activation was determined by co-culturing CL3
TCR
+ CD4
+ or CL3 TCR
+ CD8
+ cells (10
4) with target cells
CaPo13 or CapoLCL (4610
4) in flat 96 wells for 48 hours.
Blocking mAbs W6/32, L243 and OKT8 were added at 1.0 mg/
mL. Direct comparison of CL3 TCR
+ CD4
+ and CL3 TCR
+
CD8
+ cells Ag responsiveness was performed by co-culturing
effector T cells (10
4) with CaPo13 diluted at different percentages
in COS7 cells (total target cells 4610
4) for 48 hours. As control the
two trasduced T cell lines were activated with 1 mg/ml Ionomycin




+ T cell line killing activity was analyzed by
CD107 mobilization or
51Cr release assay. T cells (2610
4) were
co-cultured with CaPo13, CapoLCL or MR232 (2610
4) in the
presence of 1 ml of CD107a-PE (Ebioscience) for 5 hours. The cells
were washed with 0.02% azide and 0.5 mM EDTA, stained with
anti-Va12-FITC mAb (Pierce Endogen) and analyzed by flowcyto-
metry. Killing by
51Cr release was assessed by 4 h coculture
between the CL3 TCR
+CD8
+ T cell line and CaPo13 cells with or
without anti-MHC class I (HLA-A, B, C) or anti-MHC class II
(HLA-DR) mAbs as described previously. Effector/target (E/T)
ratio ranged between 100:1 and 1:1.
Supporting Information
Table S1 N-region specific probes for oligotyping analysis.
Found at: doi:10.1371/journal.pone.0012014.s001 (0.30 MB TIF)
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